|
C6ORF35 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.74855743404623E-14 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.26769772036096E-12 |
| Normal-vs-Stage2 |
4.635500E-04 |
| Normal-vs-Stage3 |
5.30686605770825E-14 |
| Normal-vs-Stage4 |
1.62436730732907E-12 |
| Stage1-vs-Stage2 |
1.198630E-01 |
| Stage1-vs-Stage3 |
1.287970E-02 |
| Stage1-vs-Stage4 |
3.79120000000288E-05 |
| Stage2-vs-Stage3 |
2.016400E-03 |
| Stage2-vs-Stage4 |
5.99869999999836E-05 |
| Stage3-vs-Stage4 |
1.091590E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.99200722162641E-16 |
| Normal-vs-AfricanAmerican |
1.95100000044413E-07 |
| Normal-vs-Asian |
3.04709999998654E-06 |
| Caucasian-vs-AfricanAmerican |
8.958200E-01 |
| Caucasian-vs-Asian |
2.512200E-01 |
| AfricanAmerican-vs-Asian |
4.633400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.80290260288052E-11 |
| Normal-vs-Female |
7.02771174587724E-14 |
| Male-vs-Female |
5.637800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.5177969991953E-11 |
| Normal-vs-Age(41-60Yrs) |
1.77602377249286E-12 |
| Normal-vs-Age(61-80Yrs) |
1.9776003057359E-10 |
| Normal-vs-Age(81-100Yrs) |
1.50093999999878E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.155000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.459800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.370200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.179600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.748000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.749600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.03480000013256E-07 |
| Classical-VS-Follicular |
1.833270E-04 |
| Classical-VS-Other |
5.368200E-01 |
| Classical-VS-Normal |
1.66855418370915E-12 |
| Tall-VS-Follicular |
8.89166518192042E-12 |
| Tall-VS-Other |
2.354000E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
9.393500E-02 |
| Follicular-VS-Normal |
1.404080E-03 |
| Other-VS-Normal |
1.214670E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.31160002250874E-09 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
3.30909999957107E-07 |
|
|
